Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
RGRegulus Therapeutics Inc. logo

Regulus Therapeutics Inc. (RGLS)

NASDAQ Capital Market · Currency in USD
$8.16 ▲ +0.00 (+0.00%)
At close: Jun 25, 4:00 PM ET. Market closed.

Summary

Previous Close
$8.16
Open
$8.16
Day's Range
$8.16 – $8.16
52 Week Range
$0.83 – $8.35
Volume
8,756,394
Avg. Volume
2,475,632
Market Cap
$564.95M
Beta (5Y Monthly)
0.37
PE Ratio (TTM)
--
EPS (TTM)
-$0.82
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$7.00

Profile: Regulus Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
34
CEO
Joseph P. Hagan

Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition.

Earnings

DateEst.Actual
Aug 14, 2025-$0.23-$0.17Beat
May 8, 2025-$0.29-$0.15Beat
Mar 13, 2025-$0.22-$0.20Beat
Nov 7, 2024-$0.18-$0.21Miss
Aug 8, 2024-$0.17-$0.17Beat
May 9, 2024-$0.15-$0.29Miss

Analyst view

Consensus price target
$7.00 ▼ -14.2%
Range $7.00 – $7.00
Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on RGLS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.